全文获取类型
收费全文 | 430篇 |
免费 | 19篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 6篇 |
基础医学 | 30篇 |
临床医学 | 6篇 |
内科学 | 180篇 |
皮肤病学 | 2篇 |
神经病学 | 9篇 |
特种医学 | 1篇 |
预防医学 | 1篇 |
眼科学 | 2篇 |
药学 | 98篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 7篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 15篇 |
2013年 | 24篇 |
2012年 | 21篇 |
2011年 | 27篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 23篇 |
2007年 | 36篇 |
2006年 | 30篇 |
2005年 | 30篇 |
2004年 | 31篇 |
2003年 | 32篇 |
2002年 | 26篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 12篇 |
1998年 | 9篇 |
1997年 | 3篇 |
1996年 | 5篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1983年 | 2篇 |
1908年 | 1篇 |
1899年 | 1篇 |
1898年 | 1篇 |
1896年 | 2篇 |
1895年 | 1篇 |
1893年 | 3篇 |
1891年 | 1篇 |
1888年 | 1篇 |
排序方式: 共有450条查询结果,搜索用时 15 毫秒
81.
82.
Hehlmann R Grimwade D Simonsson B Apperley J Baccarani M Barbui T Barosi G Bassan R Béné MC Berger U Büchner T Burnett A Cross NC de Witte TJ Döhner H Dombret H Einsele H Engelich G Foà R Fonatsch C Gökbuget N Gluckman E Gratwohl A Guilhot F Haferlach C Haferlach T Hallek M Hasford J Hochhaus A Hoelzer D Kiladjian JJ Labar B Ljungman P Mansmann U Niederwieser D Ossenkoppele G Ribera JM Rieder H Serve H Schrotz-King P Sanz MA Saussele S;European LeukemiaNet 《Haematologica》2011,96(1):156-162
The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends. 相似文献
83.
84.
Sharvari Bhagwat Uta Schilling Mong-Jen Chen Xiangyin Wei Renishkumar Delvadia Mohammad Absar Bhawana Saluja Günther Hochhaus 《Pharmaceutical research》2017,34(12):2541-2556
Purpose
The ability of two semi-mechanistic simulation approaches to predict the systemic pharmacokinetics (PK) of inhaled corticosteroids (ICSs) delivered via dry powder inhalers (DPIs) was assessed for mometasone furoate, budesonide and fluticasone propionate.Methods
Both approaches derived the total lung doses and the central to peripheral lung deposition ratios from clinically relevant cascade impactor studies, but differed in the way the pulmonary absorption rate was derived. In approach 1, the rate of in vivo drug dissolution/absorption was predicted for the included ICSs from in vitro aerodynamic particle size distribution and in vitro drug solubility estimates measured in an in vivo predictive dissolution medium. Approach 2 derived a first order absorption rate from the mean dissolution time (MDT), determined for the test formulations in an in vitro Transwell® based dissolution system.Results
Approach 1 suggested PK profiles which agreed well with the published pharmacokinetic profiles. Similarly, within approach 2, input parameters for the pulmonary absorption rate constant derived from dissolution rate experiments were able to reasonably predict the pharmacokinetic profiles published in literature.Conclusion
Approach 1 utilizes more complex strategies for predicting the dissolution/absorption process without providing a significant advantage over approach 2 with regard to accuracy of in vivo predictions.85.
Lundán T Juvonen V Mueller MC Mustjoki S Lakkala T Kairisto V Hochhaus A Knuutila S Porkka K 《Haematologica》2008,93(2):178-185
86.
Rifampin microspheres were prepared by spray drying using either polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PLGA) polymers in different drug to polymer ratios (90:10 to 5:95, w/w). The in-vitro release characteristics, particle-size distribution, and cytotoxicity (in an alveolar macrophage cell line) and pharmacokinetics in rats after pulmonary instillation were evaluated. Increasing the polymer content from 10% to 95% slowed down the in vitro drug release with PLGA particles showing a steeper change with increasing polymer content (100% to 20% drug release over 6 h) than PLA particles (88% to 42% drug release over 6 h). PLA microsphere formulations revealed lack of cytotoxicity and a mass median aerodynamic diameter (MMDA) of 2.22-2.86 mum, while PLGA particles were larger (MMDA of 4.67-5.11 mum). Pharmacokinetics differed among the formulations with the 10% PLA formulation showing a distinct sustained release (t (max) of 2 h vs 0.5 h of free drug) and a systemic bioavailability similar to that of free drug. Formulations with high polymer content showed a lower relative bioavailability (30%). This suggested that an optimal release rate existed for which a distinct amount of drug was delivered over an extended period of time. 相似文献
87.
Fluticasone furoate is a novel glucocorticoid developed for the treatment of allergic rhinitis and other inflammatory diseases. Fluticasone furoate demonstrates high systemic clearance, low oral bioavailability and low absolute bioavailability after intranasal administration (<0.5%). The drug possesses a high receptor affinity. Fluticasone furoate is given once daily at a dose of 110 microg. Clinical studies tested the efficacy of fluticasone furoate in seasonal allergic rhinitis and perennial allergic rhinitis. Patients randomized to the drug experienced significant alleviation in their nasal and ocular symptoms as well as clinically relevant improvement in quality of life. The drug is well tolerated and has a good safety profile owing to reduced systemic exposure. Thus, fluticasone furoate might represent a single treatment option for nasal and ocular symptoms of allergic rhinitis. 相似文献
88.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study 总被引:29,自引:40,他引:29
Sawyers CL Hochhaus A Feldman E Goldman JM Miller CB Ottmann OG Schiffer CA Talpaz M Guilhot F Deininger MW Fischer T O'Brien SG Stone RM Gambacorti-Passerini CB Russell NH Reiffers JJ Shea TC Chapuis B Coutre S Tura S Morra E Larson RA Saven A Peschel C Gratwohl A Mandelli F Ben-Am M Gathmann I Capdeville R Paquette RL Druker BJ 《Blood》2002,99(10):3530-3539
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52% of patients and sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. For patients with a sustained response, the estimated median response duration was 10 months. Imatinib induced major cytogenetic responses in 16% of patients, with 7% of the responses being complete. Median survival time was 6.9 months. Nonhematologic adverse reactions were frequent but generally mild or moderate. Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of cytopenia, skin disorders, or gastrointestinal reactions. These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis. Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs. 相似文献
89.
The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients' history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML. 相似文献
90.
Larson RA Yin OQ Hochhaus A Saglio G Clark RE Nakamae H Gallagher NJ Demirhan E Hughes TP Kantarjian HM le Coutre PD 《European journal of clinical pharmacology》2012,68(5):723-733